title: The global intellectual property landscape of induced pluripotent stem cell technologies.
authors.affiliation: Oxford-University College London Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK.
authors.forename: MacKenna
authors.initials: M
authors.lastname: Roberts
authors.affiliation: 1] Oxford-University College London Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK. [2] Department of Biochemical Engineering, University College London, London, UK. [3] Department of Nanobiomedical Science and BK21 Plus NBM, Global Research Center of Regenerative Medicine, Dankook University, Cheonan, Republic of Korea. [4] Biomaterials and Tissue Engineering Lab, Department of Nanobiomedical Science and World Class University Research Center, Dankook University, Cheonan, Republic of Korea.
authors.forename: Ivan B
authors.initials: IB
authors.lastname: Wall
authors.affiliation: IP Asset LLP, Oxford, UK.
authors.forename: Ian
authors.initials: I
authors.lastname: Bingham
authors.affiliation: IP Asset LLP, Oxford, UK.
authors.forename: Dominic
authors.initials: D
authors.lastname: Icely
authors.affiliation: The Harvard Stem Cell Institute, Cambridge, Massachusetts, USA.
authors.forename: Brock
authors.initials: B
authors.lastname: Reeve
authors.affiliation: Sartorius Stedim, Göttingen, Germany.
authors.forename: Kim
authors.initials: K
authors.lastname: Bure
authors.affiliation: 1] Oxford-University College London Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK. [2].
authors.forename: Anna
authors.initials: A
authors.lastname: French
authors.affiliation: 1] Oxford-University College London Centre for the Advancement of Sustainable Medical Innovation, University of Oxford, Oxford, UK. [2] The Harvard Stem Cell Institute, Cambridge, Massachusetts, USA. [3] Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford, Oxford, UK. [4] Centre for Behavioural Medicine, UCL School of Pharmacy, University College London, London, UK. [5].
authors.forename: David A
authors.initials: DA
authors.lastname: Brindley
mesh_terms: D001709:Biotechnology; D057026:Induced Pluripotent Stem Cells; D018973:Intellectual Property; D038622:Internationality; D010330:Patents as Topic
references.citation: Stem Cell Res Ther. 2013 Aug 14;4(4):98
references.pmid: 23953837
references.citation: Nat Med. 2013 May;19(5):510
references.pmid: 23652082
references.citation: Yale J Health Policy Law Ethics. 2009 Winter;9(1):52-127
references.pmid: 19388486
references.citation: Nat Biotechnol. 2013 May;31(5):376
references.pmid: 23657381
references.citation: Nat Biotechnol. 2010 Jun;28(6):557-9
references.pmid: 20531331
references.citation: Science. 1998 May 1;280(5364):698-701
references.pmid: 9563938
references.citation: Science. 2013 Aug 9;341(6146):651-4
references.pmid: 23868920
references.citation: Cell. 2007 Nov 30;131(5):861-72
references.pmid: 18035408
references.citation: Sci Transl Med. 2012 Feb 22;4(122):122cm3
references.pmid: 22357536
references.citation: Science. 2007 Dec 21;318(5858):1917-20
references.pmid: 18029452
references.citation: Science. 2011 Feb 11;331(6018):725-7
references.pmid: 21311015
references.citation: Lancet. 2012 Feb 25;379(9817):713-20
references.pmid: 22281388
references.citation: Nat Biotechnol. 2009 Nov;27(11):977-9
references.pmid: 19898444
references.citation: Cell Stem Cell. 2013 May 2;12(5):508-12
references.pmid: 23642360
references.citation: Nat Biotechnol. 2007 Apr;25(4):419-24
references.pmid: 17420745